Consensus EPS · Q1 2026
$0.72
Consensus revenue · Q1 2026
$13.8B
Analysts
13
Expected report
May 5, 2026
Analyst consensus (locked)
Analyst consensus
Based on estimates from 13 analysts.
| Metric | Low | Consensus | High |
|---|---|---|---|
| Revenue | $13.3B | $13.8B | $14.2B |
| EPS | $0.56 | $0.72 | $0.81 |
| EBITDA | $4B | $4.1B | $4.2B |
| EBIT | $2.9B | $2.9B | $3B |
| Net income | $3.7B | $4.1B | $5B |
Historical beat/miss
Actual reported results vs. analyst consensus at the time. Positive = beat, negative = miss.
| Period | Rev. actual | Rev. est. | Rev. surprise | EPS actual | EPS est. | EPS surprise |
|---|---|---|---|---|---|---|
| Q4 2025 | $17.6B | $16.8B | +4.2% | $0.66 | $0.57 | +16.4% |
Estimate revisions
How analyst consensus estimates have changed over the past 90 days.
Revision trends appear once we have collected at least two daily snapshots for this period.
Community vs analysts
See how the TickerLeague crowd's forecast stacks up against Wall Street.
Be the first to predict
No community consensus for Pfizer (PFE) Q1 2026 yet. Make a prediction to start the crowd forecast.
Analyst price target
Based on price targets from 2 analysts.
| Low | Consensus | Median | High | Current | Upside |
|---|---|---|---|---|---|
| $25.00 | $27.00 | $27.00 | $30.00 | $26.04 | +3.7% |
Upside calculated vs most recent trading price of $26.04.
Consensus across all covering analysts. See the ranking ›
Analyst ratings
Consensus: Hold — based on 39 analyst ratings.
12-month trend
Recent analyst actions
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 29, 2026 | Citigroup | maintain | Neutral | Neutral |
| Apr 20, 2026 | RBC Capital | maintain | Underperform | Underperform |
| Apr 13, 2026 | UBS | maintain | Neutral | Neutral |
| Apr 10, 2026 | Morgan Stanley | maintain | Equal Weight | Equal Weight |
| Apr 9, 2026 | B of A Securities | maintain | Neutral | Neutral |
| Mar 24, 2026 | Guggenheim | maintain | Buy | Buy |
| Mar 17, 2026 | HSBC | maintain | Buy | Buy |
| Mar 2, 2026 | Argus Research | upgrade | Hold | Buy |
| Feb 9, 2026 | Freedom Broker | maintain | Buy | Buy |
| Feb 4, 2026 | Cantor Fitzgerald | maintain | Neutral | Neutral |
Pfizer (PFE) Key Financials
Charts, filings, and peer comparison for every metric
Frequently asked questions
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation